WuXi PharmaTech and PRA believe they have a bright future in China together, and they've picked up the founding CEO of Theorem Clinical Research to lead them there.
Diagnostics outfit Corgenix is upping its stake in the contract manufacturing game, inking a deal with EDP Biotech to produce a colon cancer test.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
German genomics contractor Blackfield locked up a deal with AstraZeneca, agreeing to provide its computational biology technology to help the drugmaker validate an in-development cancer therapy.
Theorem Clinical Research has inked a deal with Emergo Group, pooling their resources to provide regulatory consultation to makers of medical devices and in vitro diagnostics.
Amid mounting pressure to rein in loosely regulated trials, India has clamped down on approving studies, but the resulting slowdown has scared off CROs, sponsors and other researchers, according to a report.
Following its marked growth over the past few years, New Jersey's Catalent is consolidating its drug delivery operation and teaming up with a drug developer to push a new influenza treatment forward.
More and more, academic researchers are turning to CROs to pitch in on early-stage projects, but schools could better optimize how they use contractors, according to a report in Nature.
For years, India's poor have been recruited into clinical trials with the promise of life-saving treatment, often without proper consent or education on side effects. Now, as the country works to tighten its regulations, more and more families are suing for retribution.
After more than doubling its capacity over the past year, Blue Sky BioServices has appointed a new CEO, looking to increase its share of the preclinical research market.
Parexel has united with the Rutgers New Jersey Medical School in a long-term deal to host clinical trials on campus, giving the school a boost to its clinical research unit.
While pharma's cost-cutting has long been a boon to CROs that can do R&D on the cheap, a lack of early-stage compounds coming down the pike has put the squeeze on labs that focus on preclinical and Phase I services.
CRO Theorem Clinical Research has locked down a new credit line with GE Capital, allowing it to draw funds for future acquisitions and expand its footprint.
MMS Holdings, a CRO focused on regulatory submissions, has signed on with Datatrak to use the company's cloud-based data management platform.
Roche has a taken a hands-on approach with regulating its contractors, installing staff at each of its CMOs to ensure sterility and protect against the third-party manufacturing problems that have cost its competitors time and money.
AstraZeneca has linked up with CRO Sarah Cannon Research Institute to advance its personalized medicine oncology program, partnering up to profile genes and develop responsive therapies.
Site management specialist Cenduit has made its first acquisition, buying Patient Reminders and rolling out a service that allows sponsors to communicate directly with clinical trial subjects.
Parexel International is selling off notes to raise $100 million, tapping a group of institutional investors for cash that will help it expand its capacity around the globe.
As the industry's heavyweights, up-and-comers and all in between flooded the Boston Convention Center for the annual Drug Information Association meeting, FierceCRO was on hand to take the pulse of outsourcers, app developers and clinical data wonks as they brace for changing times in the service world. In the slideshow, take a look through Fierce's trip through DIA 2013 for a glimpse at where our industry stands and where some of its leaders think it's going. Check it out >>
BOSTON--Walking through the annual Drug Information Association meeting, you can't miss the signs of consolidation, from the HCR tacked onto Synteract's logo to the buzz around PRA's corner of the conference when attendees found out it was soon to change hands for $1.3 billion. Read the feature >>